← All markets
Augur Market 0x8eae70177d0d0e524f21ba50e1251ba3ec007d2f

Will Palatin Tech's pipeline drug for female Hypoactive Sexual Desire Disorder - bremelanotide - be approved by the FDA by May 2019?

Palatin Tech submitted a New Drug Application (NDA) application for bremelanotide for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women in March 2018. Will this NDA application be approved for prescribing to patients - whether in a full or limited form by the end of May 2019? The FDA will complete it's review March 23, 2019

Open interest (ETH)
0.00 ETH
Open interest (USD)
Expires at
06/01/2019 6:59am

This market is not yet available to trade on Veil.